Boise Cascade (BCC) Lags Q1 Earnings Estimates
Boise Cascade (BCC) came out with quarterly earnings of $1.06 per share, missing the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $2.61 per share a year ago.
Boise Cascade Reports Lower Sales, Profit as Home Construction Slows
The maker of wood products said the 2025 market demands are difficult to predict, with most forecasts for housing starts ranging from flat to mid-single-digit declines, year-over-year.
Analysts Estimate Boise Cascade (BCC) to Report a Decline in Earnings: What to Look Out for
Boise Cascade (BCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boise Cascade: Priced For A Recession, But Built To Survive It
Boise Cascade, a leading wood products' manufacturer, is rated a Buy due to its strong balance sheet and long-term housing market tailwinds, despite short-term cyclical challenges. The company benefits from vertical integration, sourcing raw timber cost-effectively, and distributing finished lumber products to major retailers and builders. BCC's financial health is robust, with a low debt/equity ratio and significant cash reserves, positioning it well to weather economic downturns.
Buying A Dollar For 60 Cents: 2 Dividend Stocks With Potential Upside
The market's volatility, driven by geopolitical tensions and tariffs, has created a challenging environment. The sentiment is bearish, but I see opportunities in undervalued, high-quality companies with strong fundamentals. I focus on businesses with resilient models, growth potential, and attractive valuations. Despite headline risks, I believe in their ability to navigate uncertainty and deliver long-term returns. While risks like prolonged trade tensions or economic slowdowns exist, I remain confident in my picks, as they are well-positioned to thrive regardless of short-term market turbulence.
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results
Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcomes. An interim analysis on the ongoing study, carried out after more than half of the patients were randomized, indicated that over 60% of subjects achieved complete clinical clearance of BCC.
Boise Cascade Q4 Earnings Miss, Sales Top, Adjusted EBITDA Down Y/Y
BCC's fourth-quarter 2024 results reflect unfavorable sales price trends. Dive in to learn more about the quarterly performance.
Boise Cascade Company, Inc. (BCC) Q4 2024 Earnings Call Transcript
Boise Cascade Company, Inc. (NYSE:BCC ) Q4 2024 Earnings Conference Call February 21, 2025 11:00 AM ET Company Participants Chris Forrey - VP, Finance & IR Nathan Jorgensen - CEO & Director Kelly Hibbs - SVP, CFO, Principal Financial & Accounting Officer and Treasurer Jeff Strom - COO Conference Call Participants Kurt Yinger - D.A. Davidson Susan Maklari - Goldman Sachs Mike Roxland - Truist Securities George Staphos - Bank of America Merrill Lynch Ketan Mamtora - BMO Capital Markets Operator Good morning.
Boise Cascade (BCC) Q4 Earnings Lag Estimates
Boise Cascade (BCC) came out with quarterly earnings of $1.78 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $2.44 per share a year ago.
2 Dividend Stocks That Scream 'Trump' - And Big Potential
In light of President Trump's inauguration, I've identified two overlooked dividend stocks that could significantly benefit from a shift in political and economic trends. These stocks offer unique opportunities for long-term growth, with strong fundamentals and the potential to thrive under a Trump-led administration. If you're looking for undervalued, high-potential dividend stocks, these picks could provide the stability and growth you need to maximize your portfolio's returns.
3 Of My Favorite Income Plays For 2025
Dividend investing is more than chasing high yields or relying solely on Dividend Aristocrats. Focus on total return and consistent growth over time. I highlight three stocks combining strong yields, growth, and inflation protection, each offering unique advantages and solid long-term potential. From real estate to energy to building materials, these picks demonstrate why strategic dividend investing can outperform in any market.
Santa's Surprise - 4 Dividends I'm Buying Hand Over Fist
Market weakness, due to persistent inflation & rising rates, has created compelling buying opportunities for dividend investors. This correction offers a chance to acquire quality stocks at attractive prices. I'm focusing on companies with strong financials, secular growth, and reasonable valuations, poised to outperform in a potentially weaker market. I plan to deploy capital in January. I've highlighted compelling dividend stocks across different categories: low-yield/high-growth, and high-yield/deep-value. These are my priority buys, offering income and growth potential.
